SARS-CoV-2 Test
COVID-19
Commercial (LDT)Active
Key Facts
About NanoPin Technologies
NanoPin Technologies, founded in 2017 and headquartered in San Diego, is a private diagnostics company pioneering a nanoparticle-based platform for infectious disease detection. Its core innovation involves proprietary antibody-conjugated nanoparticles that bind to disease-specific antigen peptides present only during active infection, enabling sensitive blood-based diagnosis. The company's lead efforts target the global tuberculosis epidemic, with assays also developed for HIV and COVID-19, and it has established a key collaboration with Thermo Fisher Scientific. NanoPin operates in the Laboratory Developed Test (LDT) market while advancing its platform for broader applications.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |